U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07064486) titled 'A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia' on July 11.
Brief Summary: This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Study Start Date: June 11
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes (T2DM)
Intervention:
DRUG: BGM0504
Administered SC
DRUG: BGM0504
Administered SC
DRUG: Semaglutide
Administered SC
Recruitment Status: RECRUITING
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Disclaimer: Curated by HT Syndication....